Allergen Research Corp
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2018 | $98 M | No. 3 | $50 to $250 million | equity | SEC | |
| Nov 2016 | $157 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jan 2015 | $80 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Allergen Research Corp chose not to state its revenue in its newest notice of a funding round (Nov 2018).
SEC Form D · Nov 2018
The industry group it chose in its notices: Other Health Care.
SEC Form D · Nov 2018
That is all the official record says: Allergen Research Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: its website did not answer.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Foresite Capital Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Foresite Capital Management II, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Longitude Capital Partners II, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Longitude Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 10 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Daniel C. Adelman | Executive officer | Nov 2018 |
| Douglas T. Sheehy | Executive officer | Nov 2018 |
| Eric H. Bjerkholt | Executive officer | Nov 2018 |
| Jayson D.A. Dallas | Executive officer | Nov 2018 |
| Mary M. Rozenman | Executive officer | Nov 2018 |
| Susan E. Barrowcliffe | Executive officer | Nov 2018 |
| Jeffrey H. Knapp | Executive officer | Mar 2018 |
| Stephen G. Dilly, Jr. | Executive officer | Mar 2018 |
| Victor G. Colunga | Executive officer | Mar 2015 |
| Brett K. Haumann | Director | Nov 2018 |
| Gregory E. Behar | Director | Nov 2018 |
| Jayson D.A. Dallas | Director | Nov 2018 |
| Kathryn E. Falberg | Director | Nov 2018 |
| Mark D. McDade | Director | Nov 2018 |
| Mark T. Iwicki | Director | Nov 2018 |
| Patrick G. Enright | Director | Nov 2018 |
| Stacey D. Seltzer | Director | Nov 2018 |
| Stephen G. Dilly, Jr. | Director | Mar 2018 |
| Bryan L. Walser | Director | Mar 2015 |
| James D. Tananbaum | Director | Mar 2015 |
| Joonkyoo (Anthony) L. Yun | Director | Mar 2015 |
About
Company in London, United Kingdom.